HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fell, H. P. Articles by Bajorath, J. Search for Related Content PubMed PubMed Citation Articles by Fell, H. P. Articles by Bajorath, J. Social Bookmarking                      What's this?

J. Biol. Chem., Vol. 267, Issue 22, 15552-15558, Aug, 1992

Chimeric L6 anti-tumor antibody. Genomic construction, expression, and characterization of the antigen binding site

HP Fell, MA Gayle, D Yelton, L Lipsich, GL Schieven, JS Marken, A Aruffo, KE Hellstrom, I Hellstrom and J Bajorath
Bristol-Myers Squibb Pharmaceutical Research Institute, Seattle, Washington 98121.

We report the cloning of the genomic variable region genes of the human carcinoma reactive murine monoclonal antibody L6 and their genetic linkage to human constant region exons to encode a human IgG1/kappa chimeric antibody. The chimeric protein was produced at levels greater than 20 micrograms/ml (enabling the initiation of clinical trials) and was found to have binding properties identical with that of the murine parent. The nucleic acid sequence of the variable regions was determined and found to be different than that previously reported (1). The deduced amino acid sequence was then used to generate a structural homology based three-dimensional model of the antibody binding site, which was found to share features with antibodies known to interact with a protein surface, but distinct from those that bind to carbohydrate epitopes. Biochemical analysis of binding between antibody and the in vitro-translated product of a cDNA clone that confers L6 immunoreactivity demonstrates that the antibody recognizes a protein epitope encoded by this transcript which requires the presence of membranes, but is unaffected by the removal of carbohydrate side chains.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				S. J. DeNardo, G. L. DeNardo, A. Natarajan, L. A. Miers, A. R. Foreman, C. Gruettner, G. N. Adamson, and R. Ivkov Thermal Dosimetry Predictive of Efficacy of 111In-ChL6 Nanoparticle AMF-Induced Thermoablative Therapy for Human Breast Cancer in Mice J. Nucl. Med., March 1, 2007; 48(3): 437 - 444. [Abstract] [Full Text] [PDF]

				S. J. DeNardo, G. L. DeNardo, L. A. Miers, A. Natarajan, A. R. Foreman, C. Gruettner, G. N. Adamson, and R. Ivkov Development of Tumor Targeting Bioprobes (111In-Chimeric L6 Monoclonal Antibody Nanoparticles) for Alternating Magnetic Field Cancer Therapy Clin. Cancer Res., October 1, 2005; 11(19): 7087s - 7092s. [Abstract] [Full Text] [PDF]

				G. L. DeNardo, S. J. DeNardo, J. J. Peterson, L. A. Miers, K. S. Lam, C. Hartmann-Siantar, and K. R. Lamborn Preclinical Evaluation of Cathepsin-degradable Peptide Linkers for Radioimmunoconjugates Clin. Cancer Res., September 1, 2003; 9(10): 3865S - 3872. [Abstract] [Full Text] [PDF]

				P. A. Burke, S. J. DeNardo, L. A. Miers, K. R. Lamborn, S. Matzku, and G. L. DeNardo Cilengitide Targeting of {alpha}v{beta}3 Integrin Receptor Synergizes with Radioimmunotherapy to Increase Efficacy and Apoptosis in Breast Cancer Xenografts Cancer Res., August 1, 2002; 62(15): 4263 - 4272. [Abstract] [Full Text] [PDF]

				H.-K. Guttormsen, A. H. Sharpe, A. K. Chandraker, A. K. Brigtsen, M. H. Sayegh, and D. L. Kasper Cognate Stimulatory B-Cell-T-Cell Interactions Are Critical for T-Cell Help Recruited by Glycoconjugate Vaccines Infect. Immun., December 1, 1999; 67(12): 6375 - 6384. [Abstract] [Full Text] [PDF]

				M.-C. Shanafelt, I. Kang, S. W. Barthold, and L. K. Bockenstedt Modulation of Murine Lyme Borreliosis by Interruption of the B7/CD28 T-Cell Costimulatory Pathway Infect. Immun., January 1, 1998; 66(1): 266 - 271. [Abstract] [Full Text] [PDF]

				C. B. Siegall, S. S. Bacus, G. D. Plowman, B. Mixan, D. Chace, D. M. Chin, A. Goetze, J. M. Green, I. Hellström, and H. P. Fell HER4 Expression Correlates with Cytotoxicity Directed by a Heregulin-Toxin Fusion Protein J. Biol. Chem., March 31, 1995; 270(13): 7625 - 7630. [Abstract] [Full Text] [PDF]

				M.G. Emara, S.R.C. Malburg, and J.S. Lam Expression of an anti-Pseudomonas aeruginosa lipopolysaccharide core recombinant antibody in Escherichia coli Innate Immunity, February 1, 1995; 2(1): 53 - 61. [Abstract] [PDF]

				B. Finck, P. Linsley, and D Wofsy Treatment of murine lupus with CTLA4Ig Science, August 26, 1994; 265(5176): 1225 - 1227. [Abstract] [PDF]